FDA approves label changes on DPD deficiency for fluorouracil injection productsNov 10Regulatory decisionfluorouracil
FDA approves fruquintinib for refractory metastatic colorectal cancerNov 6Regulatory decisionfruquintinib
Cardiff Oncology posts results for terminated onvansertib pancreatic cancer trialNov 4Trial updateCardiff Oncology
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Merck registers new MK-8644 psoriasis trial; RA and HIV/HPV vaccine trials continueOct 30Weekly roundup, 11 itemscabazitaxeldexamethasoneUpdated
Johns Hopkins-sponsored HCC trial of Nivolumab plus Relatlimab posts results, now not recruitingOct 29Weekly roundup, 2 itemsBristol Myers Squibbnavlimetostat
AstraZeneca completes balcinrenone/dapagliflozin PK study; posts two new observational trialsOct 23Weekly roundup, 12 itemsabemaciclibAstraZeneca
Lilly posts two DC-806 Phase 1 DDI results; registers three new Phase 3 trialsOct 22Weekly roundup, 11 itemscetuximabdulaglutide
Oncolytics reports faster enrollment in REO 033 colorectal cancer studyOct 1Trial updateCoherus Oncology, Inc.Oncolytics BiotechUpdated
AbbVie registers Phase 1 trial comparing upadacitinib, tofacitinib, baricitinib in healthy adultsSep 30Weekly roundup, 4 itemsABBV-722AbbVie
CytomX reports Q2 2026 results, advances Varseta-M toward first registrational studyAug 6Quarterly updateCytomX Therapeutics
XBiotech posts results for XB2001 pancreatic cancer trial, over five years after registrationAug 4Trial updateXB2001XBiotech, Inc.